Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1011.1
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1011.1 is a next-generation seasonal influenza vaccine candidate developed by Moderna. It is an mRNA-based vaccine encapsulated in lipid nanoparticles (LNPs) designed to encode for hemagglutinin (HA) proteins from multiple influenza strains. As part of Moderna's next-generation flu program, mRNA-1011 is a pentavalent vaccine, meaning it targets the four standard WHO-recommended seasonal strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata) plus an additional H3N2 strain to provide broader protection against the diversity of circulating H3N2 viruses. The .1 designation refers to a specific version or formulation being compared against other candidates (like mRNA-1011.2 and mRNA-1012.1) in Phase 1/2 clinical trials to optimize safety and immunogenicity in older adults.
- Other names
- mRNA-1011.1mRNA1011.1mRNA 1011.1
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-1011.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1011.1.